Dazhi Xu
Dazhi Xu
Shanghai, China2 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Active, not recruiting | Phase 2 | 2026-08-11 | NCT05468138 | |
| S-1 for 9 Months Versus 1 Year for Stage II Gastric Cancer (SMAC） | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric cancer, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 3 | 2019-05-31 | NCT03941561 |